# Twin SUBLIVAC® Grasses Clinical Efficacy Study

> **NCT00422149** · PHASE3 · COMPLETED · sponsor: **HAL Allergy** · enrollment: 350 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal
- Conjunctivitis, Allergic

## Interventions

- **DRUG:** SUBLIVAC® Grasses/Placebo treatment
- **DRUG:** SUBLIVAC® Grasses treatment
- **DRUG:** Placebo treatment

## Key facts

- **NCT ID:** NCT00422149
- **Lead sponsor:** HAL Allergy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2012-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422149, "Twin SUBLIVAC® Grasses Clinical Efficacy Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00422149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*